In vitro biodegradation, blood, and cytocompatibility studies of a bioactive lithium silicate glass-ceramic

Abstract

This study investigates a novel non-stoichiometric lithia-silica glass-ceramic (Bioactive LD) designed for bone tissue engineering applications. Incorporating SiO2–Li2O–CaO–P2O5–K2O–SrO–ZnO, the glass-ceramic underwent optimized thermal treatments resulting in a composition predominantly of lithium disilicate (Li2Si2O5 - 87 %) with a minor lithium phosphate phase (Li3PO4 - 13 %). Structural analysis using X-ray diffraction (XRD) and scanning electron microscopy (SEM) revealed a refined microstructure with Li2Si2O5 crystals in rod form with a high aspect ratio of around 4:1. Expanding on previous work, this study investigates the in vitro osteoblastic response of Bioactive LD compared to a commercial glass-ceramic (E-Max CAD®). The evaluation, employing live/dead assays, resazurin assays, and alkaline phosphatase activity measurements at different time points, demonstrated comparable cell viability and proliferation on both glass-ceramics. The chemical stability of the samples was tested, and the Bioactive LD showed a higher amount of leached ions in the solution, without significant mass loss, consistent with the standardized values for a class 4 material (ISO 6872), with no significant change in its microstructure. The chemical solubility tests were investigated employing SEM and energy dispersive X-ray analysis (EDS), giving insights into the role of leached ions in the microstructure and bioactivity of the materials. Notably, Bioactive LD exhibits higher alkaline phosphatase activity, indicating enhanced stimulation of osteoblastic cells. Additionally, the Bioactive LD promotes mineralization matrix production, as evidenced by alizarin red S staining. The study also employs SEM-EDS to evaluate the formation of apatite mineralized matrix. Bioactive LD exhibits a homogeneous mineralized matrix with increased Calcium and Sulfur signals, suggesting early hydroxyapatite formation after Alizarin Red S assay. In contrast, Commercial LD shows limited reactivity and bioactivity, with no substantial calcium deposition. An indirect cytotoxicity test indicates minimal cytotoxicity for Bioactive LD, while Commercial LD exhibits slight cytotoxicity, consistent with findings from the literature. The results highlight Bioactive LD's potential for bone regeneration, emphasizing its enhanced bioactivity and the formation of a complex mineralized matrix that could contribute to improved bone integration properties.